Mongrel or beagle dogs were submitted to bile duct ligation. or to extraenteric biliary diversion by means of choledochoureter08tomy. The kinetics of intravenously administered FK508 was not changed from control status two weeks after bile duct ligation. but the bioavailability of orally administered FK508 was nearly quadrupled. Following oral administration. the absorption of FK508 was highly variable. The results indicate that in dogs FK508 is absorbed from the intestine just as efficiently in the absence of enteric bile and in presence of exogenous bile salt supplement when compared with its absorption in presence of normal bile drainage. These findings with FK508 are different from those with cyclosporine after biliary obstruction or diversion and will have important practical as well as experimental ramifications.
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• Falk Clinic. University of Pittsburth. Pittsburth, PA, 15213. immunosuppressant in rats, dogs, monkeys, baboons. and humans after liver, kidney, or heart transplantation (2). FK506 is largely metabolized by the liver prior to elimination from the body (3) and the status of the liver is expected to influence its elimination. Since liver dysfunction or bile duct ligation decreases the availability of bile salts for solubilization of lipid soluble drugs, normal biliary drainage was predicted to be an important condition for the optimal absorption of FK506, as is the case with absorption of oral cyclosporine (4) . In the present study, this expectation could not be supported in dogs submitted to bile duct ligation or extraenteric biliary diversion. Five days later. the common bile and cystic ducts were doubly ligated and divided under general anesthesia with pentobarbital-halothane anesthesia. The animals were given 1 g/day intramuscular cefamandole for three days postoperatively. Then 14 days later. the FK506 kinetic studies were performed in the same way as described preoperatively.
MATERIALS AND METHODS

Bile
Biliary diversion with choledochoureterostomy. Female beagle dogs (n-6) weighing approximately 10 kg and with the conditions described above were given an oral dose of 1 mg/kg FK506 and blood samples were obtained at 0, 0.25, 0.5, 0.75. 1. 2, 3. 4, 6, 8. 12, 16 . and 24 hr. Three days later, the dogs received 1 mg/kg of FK506 orally, 15 min after 1 g of lecithin and 250 mg of chenodeoxycholic acid. and FK506 kinetics was studied as described earlier. Nine days later, choledochoureterostomy was performed after right nephrectomy, using a previously described technique (5) . Intramuscular cefamandole was used as in the previous section. Two weeks after biliary diversion, the oral FK506 absorption study was repeated, first with out any exogenous bile supplement and three days later, after administration of 250 mg chenodeoxycholic acid and 1 g lecithin.
Blood samples were centrifuged at room temperature and the plasma was frozen at -70·C until analyzed for FK506. The FK506 concentration was measured in plasma by Tamura's enzyme immunoassay method (6) . This assay has a coefficient of variation of 22% at 0.5 ngl ml and 10% at 2.1 ng/m!. Liver function tests were carried out at the outset, and at the time of the subsequent studies.
The plasma concentration time curve was analyzed by standard techniques (7) . Statistical Analysis was carried out using a nonparametric test (Mann Whitney's U test). t test, or ANOV A as appropriate, with P<0.05 being statistically significant.
RESULTS
Bile duct ligation. Serum GOT, GPT, alkaline phosphatase, and total bilirubin were in the normal range before bile duct ligation and were elevated in all of the dogs after bile duct ligation (Table O . While serum creatinine was lower after surgery, the BUN was normal throughout. Table 2 describes the biochemical parameters in dogs before and after biliary diversion. While the serum GOT and GPT were normal after biliary diversion, alkaline phosphatase and total bilirubin were slightly elevated after surgery, indicating minimal changes in the hepatic function.
The plasma concentration-versus-time curve following intravenous administration of FK506 to a mongrel dog (No.6) before and after bile duct ligation is shown in Figure 1 . The kinetics of FK506 in dogs can be adequately described by a two-compartment model, with a rapid initial distribution phase followed by a slower disposition phase. The pharmacokinetic Tables 3  and 4 for mongrel and beagle dogs, before and after bile duct ligation. Bile duct ligation did not significantly alter the disposition rate constant, half life, or the plasma clearance of FK506 in this group of dogs. However, the volume of distribution of FK506 was significantly increased in the mongrel dogs after bile duct ligation (P<O.05).
The plasma concentration-versus-time curve following oral administration of FK506 to dog No.3 before and after bile duct ligation is shown in Figure 2 . The pharmacokinetic parameters calculated in five mongrel and six beagle dogs after oral administration are listed in Tables 5 and 6 . These results indicate a rapid absorption of FK506, with a mean peak plasma concentration of 2.8 (+ 1.1) and 7.8 (+2.0) ng/ml being reached in 1.2-1.3 hr. After bile duct ligation, the disposition rate constant, half-life, and the time to reach peak plasma concentrations were significantly altered while peak plasma concentrations were not different. More importantly, there was a significant increase in the area under the plasma concentration-versustime curve (AUC). Consequently, the oral bioavailability of FK506 in bile duct ligated animals was significantly higher (3-4-fold) than that observed in normal animals.
Choledochoureterostomy. Two weeks after this operation, all 6 of the dogs had near-normal liver function teats. They were all eating and healthy. Biliary diversion or addition of exogenOlla bile salta did not reault in any significant chanpa in the peak plaama concentrations, half·life, or the AUC after oral FK506 administration. The time to reach peak plasma concen· tration was. however. increased significantly after biliary diversion (Table il. 
DISCUSSION
The pharmacokinetics of intravenous FK506 were altered very little by bile duct ligation. This is different from the effect of bile duct ligation on cyclosporine. which has a reduced elimination under these circumstances (8) . The difference between the 2 drugs given intravenously requires explanation since both agents are very lipid-soluble and are eliminated primarily by hepatic metabolism (3. 4). However. cyclosporine is cleared slowly from the body and thus is classified a8 a "lowclearance" drug, whereas FK506 has a plasma clearance that is actually higher than the hepatic blood flow.
The 2·week period of bile duct ligation probably caused minimal impairment of the hepatic blood flow in these dogs in spite of the significant but moderate hepatic injury that was measurable by standard liver function tests. Since FK506 appears to be a high-clearance drug and its elimination after i.v. administration depends on hepatic blood flow. severe liver dysfunction leading to reduced hepatic blood flow would be expected eventually to be a factor that would decreue the elimination of intravenously administered FK506. Apparently, this had not yet occurred within 14 days of duct ligation in both mongrel and beagle dogs.
In contrast to the minimum changes in intravenous pharmacokinetics, the oral pharmacokinetics of FK506 were drastically altered by bile duct ligation. The time to reach peak plasma FK506 concentrations and the bioavailability were significantly increased. Again, this was an unexpected finding since the bioavailability of orally administered cyciosporine is greatly reduced after bile duct ligation (8) . It is possible that presystemic metabolism of FK506 is impaired in animals after bile duct ligation resulting in increased oral bioavailability. It was not possible to explain these paradoxical results completely without further experimentation in additional dogs who had pure biliary diversion, which was done with choledochoureterostomy. This procedure eliminated the potential artifact of liver injury caused by duct ligation; hepatic function tests were minimally altered, and the livers were histopathologically normal at 2 weeks. Biliary diversion by itself did not significantly alter the extent of absorption of FKS06. The increased time to reach peak FK506 plasma concentrations following biliary diversion presumably indicates a decreased rate of absorption of FKS06. Addition of bile salts in the presence or in the absence of endogenous bile did not alter the extent of FK506 absorption.
Taking the biliary obstruction and diversion experiments together, the results indicate that absorption of FKS06, in contrast to that of cyciosporine, which is bile salt-dependent (8) (9) (10) , is actually not significantly altered by the absence of bile. The differential effect of bile on FKS06 and cyciosporine absorption can be rationalized as follows. The dose of FKS06 (about 0.15 mg/kg) is nearly one-flftieth of that of cyclosporine (about 7.S mg/kg). The fluid volume in the gut is sufficient to dissolve FK506 from the solid dispersion formulation and bile contributes minimally to FK 506 dissolution. On the other hand, bile is necessary for solubilizing the administered dose of cyclosporine and lack of bile results in decreased cyciosporine absorption.
Much further work will be required before the full explanation for this unexpected finding can be delineated. However, it is clear at a practical level that the assumption that past practices with cyciosporine will be applicable to oral FKS06 administration are unwarranted. When the draining T tube of a patient on oral cyciosporine is ciamped, it is necessary to reduce the dosage in order to prevent augmented absorption and consequent large increases in cyciosporine blood levels (11) . It has already been noted in similar patientS treated with FKS06 that downward adjustments in FKS06 dosages are not required (12, 13) .
